EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
Pharma's Medical Affairs Bridge: From Field Insights and Stakeholder Needs to Global Scientific Strategy
Medical Affairs has evolved from being primarily a supportive and educational function to becoming a strong strategic partner earlier on Through ongoi...
Advisory Board
.webp "Juris Hmelnickis")
.webp "Eiman Shafa")
KNOWLEDGE BANK
-
Articles
How AI Is Changing Revenue Management in the Pharmaceutical Industry
Pharmaceutical revenue has many moving parts A sale might involve a wholesaler a specialty pharmacy a payer and several different pricing or rebate agreements By the time the numbers reach the finance team plenty of opportunities exist for things to change or be recorded differently along the way
-
Techno Trends
Lilly’s Jaypirca Gains FDA Approval for First-Line CLL/SLL Treatment
Eli Lilly and Company has received approval from the US Food and Drug Administration FDA for an additional indication for Jaypirca pirtobrutinib in adults with previously untreated chronic lymphocytic leukaemia CLL or small lymphocytic lymphoma SLL without a known p deletion The approval enables Jaypirca to be used as a firstline treatment
-
Projects
Genentech Begins US$750 Million Expansion of Oregon Manufacturing Facility
Genentech a member of the Roche Group has started construction on a US million expansion of its manufacturing facility in Hillsboro Oregon The squarefoot project will double the existing sites footprint and increase US production capacity for advanced drug delivery devices
-
Research Insights
AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex
The pathohistological hallmarks of Parkinsons disease are aggregated alphasynuclein and other aggregationprone proteins Lewy bodies Recent studies show mechanistic as well as genetic connections between lysosomal dysfunction and Parkinsons disease pathology A direct link between lysosomal function and Parkinsons disease might be the degradation of alphasynuclein within the lysosomal system
-
White Papers
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys complexity
TOP ARTICLES
-
1
Foundation Models in Drug Discovery: The Next Frontier of Pharmaceutical Research
Lakshmi
Foundation models pretrained on vast biological corpora are replacing the one-model-per-task economics that has long limited computational drug discovery. This article explains what makes these system...
-
2
-
3
Evolving Trends and Strategies in Pharmaceutical Marketing: Focus on the American Market
Kate Williamson
This exploration delves into evolving trends and strategies in pharmaceutical marketing, with a focus on the dynamic American market. From digital transformation and patient-centric approaches to data...
-
4
From a Nation of Comrades to VIP Individuals: The Paradigm Shift Called Precision Medicine
Dr. Emad Hassan
For more than a century, medicine has advanced by identifying similarities among patients and developing standardised therapies for large populations. Precision medicine represents a fundamental philo...
-
5
The Latest Breakthroughs in Prescription Drug Development
Kate Williamson
New classes of prescription drugs include but are not limited to the following; Personalized medicine; mRNA; gene therapy; Artificial intelligence in drug discovery; Biologics; Long acting formulation...
press releasesRead more...
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
BioCryst Pharmaceuticals Inc announced the US Food and Drug Administration FDA has approved its supplemental New Drug Application sNDA for use of the oral pellet formulation of oncedaily ORLADEYO berotralstat for prophylactic therapy in adults and adolescents aged years and older
Radical Numerics Launches Omnii-1, a New Generation of Biological AI, as First AI-Designed Phage Therapy Reaches Human Patient
Radical Numerics an AI research lab building general biological intelligence today launched Omnii a biological AI model that learns across DNA RNA proteins and other molecular data Researchers used Omnii to design a bacteriophage and administered it to a patient with a drugresistant bacterial infect...
Takara Bio USA partners with SPT Labtech to deliver automation-ready NGS library preparation technologies
Takara Bio USA Inc a wholly owned subsidiary of Takara Bio Inc and SPT Labtech today announced their partnership to deliver validated automated library preparation workflows that combine Takara Bio nextgeneration sequencing NGS library preparation chemistries with SPT Labtechs firefly liquid
Cemvita and Roebling Partner to Accelerate Industrial BioSolutions From Discovery to Deployment
Cemvita an emerging frontier AI lab for industrial BioSolutions today announced a partnership with Roebling an AInative engineering firm to speed the discovery evaluation and deployment of biological solutions for the naturalresource industries Cemvita brings more than a decade of experience develop...
Events Read more...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026PM& AC 2026
Novotel Hyderabad Convention C...
28 - 30
Oct 2026BIOPLUS-INTERPHEX Korea
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
LATEST NEWSRead more...
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
Merck known as MSD outside of the United States and Canada today announced the European Commission EC has approved KEYTRUDA pembrolizumab Mercks antiPD therapy in combination with Padcev enfortumab vedotinejfv as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment...
Verily Health and Autoimmune Registry Partner to Build Cross-Disease Research Infrastructure for Autoimmune Conditions
Verily Health Inc a healthcare data intelligence company today announced a strategic partnership with Autoimmune Registry Inc ARI a nonprofit nominated for the inaugural Prix Galien Patient First Award in Honor of Michael J Fox for its work studying autoimmune diseases the populations they affect a...
Jemperli (dostarlimab) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer
GSK plc announced the US Food and Drug Administration FDA has approved Jemperli dostarlimab as the first and only immunotherapy for adults with stage II and III microsatellite instabilityhigh MSIHmismatch repair deficient dMMR locally advanced rectal cancer under the accelerated approval pathway
Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
Alcon the global leader in eye care dedicated to helping people see brilliantly today announced it has acquired Neurotech Pharmaceuticals Inc a company focused on developing innovative cell therapies for chronic and neurodegenerative eye diseases
Qare™ Is Here: Lōkahi Therapeutics™ Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications
Lkahi Therapeutics a subsidiary of Glucotrack Inc today announced the public launch of Qare a comparative health platform designed to help users compare selfreported treatment experiences across medications within the same therapeutic class Launching initially in the GLP category Qare enables
Pulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid Center
Pulse Biosciences Inc the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation nanoPFA or nsPFA technology today announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa Florida The partnership covers both the comme...
